Neurology Central

Veledimex: a drug-inducible gene therapy approach for glioblastoma yields promising Phase I results


Researchers from Brigham and Women’s Hospital (MA, USA) and Dana-Farber Cancer Center (MA, USA) have collaborated to conduct a Phase I trial investigating a novel treatment method (veledimex) for glioblastoma.

The results of the study, which utilizes a drug-inducible gene therapy approach, have been published in Science Translational Medicine.

The approach involves activation of the human interleukin-12 (hiL-12) gene by the oral activator ligand veledimex.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.